TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An October 28 MedPage Today roundup reports that there are “zero” signs Health Secretary Robert F. Kennedy Jr. plans to leave the Trump administration after the midterms. It also says Kennedy is considering psychiatrist Shebani Sethi to lead the National Institute of Mental Health and that the administration is backing away from a planned kratom ban. The reports do not establish a final NIMH appointment or specify the terms of the kratom policy change.
A MedPage Today health-policy roundup published October 28 reported that there are “zero” signs Health Secretary Robert F. Kennedy Jr. will leave the Trump administration after the midterms, while Kennedy is reportedly considering psychiatrist Shebani Sethi to lead the National Institute of Mental Health and the administration is backing away from a planned kratom ban. The items, attributed by the roundup to Axios, Science and The New York Times, concern leadership and policy decisions affecting federal health agencies, but do not establish a final NIMH appointment or detail the revised kratom approach.
The roundup cited Axios for the assessment that there are “zero” signs Kennedy will depart after the midterms. That is a report about the current indications, not a formal statement from Kennedy or the White House confirming his future. The source material does not identify a specific decision or announcement about his tenure.
Citing Science, the roundup said Kennedy is reportedly considering Shebani Sethi, MD, a psychiatrist associated with the term “metabolic psychiatry,” to lead NIMH. It also reported that Kennedy overruled NIH Director Jay Bhattacharya, who was considering another candidate. The roundup does not say Sethi has been nominated or appointed, or provide details about the other candidate or the process ahead.
The roundup also attributed to The New York Times a report that the Trump administration is backing down from a plan to ban kratom. It did not specify what policy would replace the proposed ban, how far the change has progressed, or whether any formal action has been taken. Kratom is a plant-derived substance sold in the United States in various products; the supplied report gives no additional details about the policy’s scope or timeline.
Leadership and Substance Policy in Play
The reported developments touch two different levers of federal health policy: who may lead a major mental-health research institute and how the administration may regulate kratom. NIMH leadership can shape the institute’s priorities and management, while a change in the proposed kratom policy could affect federal oversight of products containing the substance. Neither potential outcome is settled in the source material.
Kennedy’s reported role in the NIMH search also matters to the agency’s internal decision-making. The roundup says he overruled NIH Director Jay Bhattacharya over a candidate choice, but offers no account from either official and no explanation of the disagreement. Readers should distinguish that reported intervention from a confirmed appointment or a broader change to NIH policy.
For the public, the immediate takeaway is that the administration’s direction remains under development on these issues. The report gives a snapshot of discussions and policy movement, not final decisions that establish who will lead NIMH or what federal kratom rules will be.
Products Worth Considering
Levoit Vital 100S-P Air Purifier with Washable Pre-Filter
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
Oura Ring 5 Smart Ring – Silver – Size 10
As an affiliate, we earn on qualifying purchases.
The Roundup’s Three Developments
The items appeared in a weekly roundup of public-health policy and were summarized from separate reports by other outlets. MedPage Today’s October 28 report also listed developments concerning the CDC, agency personnel, federal health initiatives and insurance policy. Those additional items form part of the roundup but are not necessary to establish the status of Kennedy’s tenure, the NIMH search or the kratom proposal.
The report links Sethi to the phrase “metabolic psychiatry”, but it does not describe her research, qualifications beyond identifying her as a psychiatrist, or her proposed plans for NIMH. Likewise, it refers to a plan to ban kratom but does not provide the original proposal’s details. The available source material therefore supports reporting the developments and their attribution, but not a fuller account of either policy debate.
Each item is presented as a report rather than a government notice. The roundup’s wording about Kennedy’s future is an assessment attributed to Axios; the NIMH account is attributed to Science; and the kratom update is attributed to The New York Times. No underlying official announcement is included in the supplied material.
““zero” signs that HHS Secretary Robert F. Kennedy Jr. will leave the Trump administration after the midterms”
— Axios, as cited by MedPage Today
Appointments and Kratom Rules Unsettled
The source material does not confirm whether Kennedy will remain in the administration after the midterms, and it provides no formal statement from him or the White House about his plans. The reported absence of signs of a departure should not be read as a guarantee of his tenure.
It is also unclear whether Kennedy has selected Sethi, whether NIH or HHS has begun a formal appointment process, or what role Bhattacharya’s reported disagreement will play. On kratom, the roundup does not identify the policy instrument, the timing of the change, or whether the administration has abandoned the ban entirely or is revising it. No final decision is documented in the supplied account.
Watch for Formal Agency Decisions
The next clear developments would be an official announcement about the NIMH director search or a formal administration statement on kratom regulation. Until then, the reported consideration of Sethi and the retreat from a ban remain developments attributed to news outlets, rather than completed government actions.
Further reporting or agency documents may clarify whether Kennedy intends to stay beyond the midterms, whether Sethi is under formal consideration, and what policy the administration plans to pursue for kratom. The source roundup gives no dates or announced milestones for those decisions.
Key Questions
Is Robert F. Kennedy Jr. leaving the Trump administration?
The roundup cited Axios for the assessment that there are “zero” signs he will leave after the midterms. It does not include a formal confirmation of his plans.
Has Shebani Sethi been appointed to lead NIMH?
No appointment is confirmed in the report. It says Kennedy is reportedly considering Sethi for the role.
What is reported about Kennedy and the NIMH search?
The roundup, citing Science, says Kennedy is considering Sethi and overruled NIH Director Jay Bhattacharya, who was considering another candidate. It does not explain the disagreement or provide further details about the search.
Is the federal kratom ban canceled?
The roundup reports that the administration is backing down from a plan to ban kratom, citing The New York Times. It does not say whether the plan has been formally canceled or describe a replacement policy.
Source: rss
